about
Genome-wide association studies identify four ER negative-specific breast cancer risk lociGenome-wide association study identifies novel breast cancer susceptibility lociAssociation of aspirin and nonaspirin nonsteroidal anti-inflammatory drugs with cancer incidence and mortalityLarge-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repairCandidate locus analysis of the TERT-CLPTM1L cancer risk region on chromosome 5p15 identifies multiple independent variants associated with endometrial cancer riskPALB2, CHEK2 and ATM rare variants and cancer risk: data from COGSGenetic modifiers of menopausal hormone replacement therapy and breast cancer risk: a genome-wide interaction study.Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer.Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European DescentNo clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.Racial differences in primary central nervous system lymphoma incidence and survival rates.Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocolComparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC)Heterogeneity of breast cancer associations with five susceptibility loci by clinical and pathological characteristics.Genes associated with histopathologic features of triple negative breast tumors predict molecular subtypes.Subtyping of breast cancer by immunohistochemistry to investigate a relationship between subtype and short and long term survival: a collaborative analysis of data for 10,159 cases from 12 studiesVariation in genes required for normal mitosis and risk of breast cancerInherited determinants of ovarian cancer survival.Ancestry-shift refinement mapping of the C6orf97-ESR1 breast cancer susceptibility locus.Variation in anastrozole metabolism and pharmacodynamics in women with early breast cancer.Association between a germline OCA2 polymorphism at chromosome 15q13.1 and estrogen receptor-negative breast cancer survivalA comprehensive examination of CYP19 variation and risk of breast cancer using two haplotype-tagging approaches.Participant-perceived understanding and perspectives on pharmacogenomics: the Mayo Clinic RIGHT protocol (Right Drug, Right Dose, Right Time)Methylation of leukocyte DNA and ovarian cancer: relationships with disease status and outcome.Identification of new genetic susceptibility loci for breast cancer through consideration of gene-environment interactions.Hospitalizations and emergency department use in Mayo Clinic Biobank participants within the employee and community health medical home.Missense variants in ATM in 26,101 breast cancer cases and 29,842 controls.Xenobiotic-Metabolizing gene polymorphisms and ovarian cancer risk.Confirmation of 5p12 as a susceptibility locus for progesterone-receptor-positive, lower grade breast cancerBreast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2ERβ1: characterization, prognosis, and evaluation of treatment strategies in ERα-positive and -negative breast cancerGenetic variation in mitotic regulatory pathway genes is associated with breast tumor gradeCommon non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association ConsortiumCentrosome-related genes, genetic variation, and risk of breast cancer.Effect of aspirin and other NSAIDs on postmenopausal breast cancer incidence by hormone receptor status: results from a prospective cohort study.MicroRNA related polymorphisms and breast cancer risk.Assessing interactions between the associations of common genetic susceptibility variants, reproductive history and body mass index with breast cancer risk in the breast cancer association consortium: a combined case-control study.The Mayo Clinic Biobank: a building block for individualized medicineCYP2B6*6 is associated with increased breast cancer risk.Association of genetic variation in genes implicated in the beta-catenin destruction complex with risk of breast cancer.
P50
Q24622610-2668B384-7BCF-4E4F-A872-EFE62C86B193Q24645441-E2945E6C-FFB8-477E-90EB-AC70095085B1Q28212542-0AFADA96-A5CB-4E4C-938D-2EEF9A0A7A1EQ28267893-A5D41C30-814F-4D0D-88E7-0047BFA393F8Q28385765-C1ADD519-D343-4076-B5B9-6CD2C0E35A7AQ28584533-DD4BB210-7BD4-42E0-99A3-3C1D75ACC680Q29417068-1C58B0BE-8723-4812-9589-B8C65BF46F06Q29417100-39AEDAC2-9ACC-419B-82CA-EFAB8677F881Q30000080-8E2C7E73-0642-4BED-A885-5382F9C09AF5Q30374367-546CC1CB-ADC8-4DC9-94D7-8BD9B86F197BQ30436018-87DEE45D-242A-4E4E-93CB-04C37D9B5A3DQ30572528-49AD8114-0B29-49A9-BE6A-5C923474087FQ31082788-8446595C-A609-4CAE-8183-C9AAEBA7387AQ33330850-CB9F1E94-5CA4-40D7-B9E1-A49707167BF9Q33589487-91520D05-B702-43DA-A7F0-B975ADB5B44BQ33593016-B852EB49-C8DE-41E6-8B7B-379FD8D1BAA2Q33636005-52EE00DD-62C7-4061-9747-0F145C69FB74Q33638923-F1FA69BE-AB37-4473-9302-279E0662F6C2Q33641475-10A45BC4-E725-41C7-A51B-1327C2D0B61CQ33793932-29F37DE3-28A5-4861-AEEA-750CA1D5274FQ33828680-D5C322CA-2FBF-4472-8F74-5C7DC43C5F44Q33844619-3C59174D-07C5-4405-8E38-320049E1BC01Q33874771-87ED2198-B6CE-45C1-9F73-04D19CD47A97Q33915396-AA1F1FC7-8081-4D65-85C9-9C8F0542730EQ34038964-B5905EE2-67BE-402E-A933-7704624CA1E0Q34119042-BB9DD6D2-64B2-4DC6-A664-D7FB7D9A849FQ34123806-415E5604-9996-4915-AE0E-385E2B5D14A9Q34177267-3402D90B-C87D-489E-B789-F61FE78D4225Q34181322-B382C140-E427-4190-8565-9CBE03BAA02FQ34327945-8D7A89A6-3AE4-4A60-AA30-DB0699E15D23Q34334131-DE295E2A-C7DB-4BA2-A844-11520BAA3BEEQ34378972-F1428550-9A26-403C-8DE4-1BC8861E7045Q34379032-6C5EABEB-151A-4221-BF09-E84D4EDB5D92Q34380497-1EDFF074-BB8C-48A6-881F-68B182D550C0Q34381496-BD285484-6909-4D01-B009-F45ACA3F0DD5Q34497352-02B3F706-B9B7-4BD2-98F4-12CCC3413A9BQ34613673-AFF42861-CFE6-43BF-A893-987DB05238ACQ34648736-C6B959A4-05D4-4CC3-A4F3-C1AB77DBC107Q34793437-A29D3667-B9EC-45C4-BBD4-08FC40E31BC6Q34809698-08DF453A-58BF-4D5E-A82C-C8DC1745E16A
P50
description
forsker
@nb
researcher
@en
name
Janet E. Olson
@da
Janet E. Olson
@de
Janet E. Olson
@en
Janet E. Olson
@es
Janet E. Olson
@fr
Janet E. Olson
@nb
Janet E. Olson
@nl
Janet E. Olson
@nn
Janet E. Olson
@sv
type
label
Janet E. Olson
@da
Janet E. Olson
@de
Janet E. Olson
@en
Janet E. Olson
@es
Janet E. Olson
@fr
Janet E. Olson
@nb
Janet E. Olson
@nl
Janet E. Olson
@nn
Janet E. Olson
@sv
altLabel
Janet E Olson
@en
Janet Olson
@en
prefLabel
Janet E. Olson
@da
Janet E. Olson
@de
Janet E. Olson
@en
Janet E. Olson
@es
Janet E. Olson
@fr
Janet E. Olson
@nb
Janet E. Olson
@nl
Janet E. Olson
@nn
Janet E. Olson
@sv
P101
P106
P2038
Janet_Olson3